Moleculin Biotech
Phase 3-stage pharmaceutical development company advancing therapies for hard-to-treat tumors and viruses. Its lead candidate, Annamycin (naxtarubicin), is a next-generation anthracycline designed to avoid multidrug-resistance mechanisms and to eliminate the cardiotoxicity common to currently prescribed anthracyclines, and is in development for relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases.
Company Info
Upcoming Milestones & Key Dates
Annamycin preclinical and translational data presented at three scientific venues, including the AACR Conference on Pancreatic Cancer
Nasdaq listing-qualifications hearing, requested by the company to stay any suspension while it contests the September 2026 staff determination on the minimum bid price rule
MIRACLE Phase 3 pivotal adaptive-design trial of AnnAraC in relapsed or refractory AML
Clinical Development Pipeline
Annamycin + cytarabine (AnnAraC)
Target: Topoisomerase II / anthracyclineAnnamycin (naxtarubicin)
Target: Topoisomerase II / anthracyclineWP1066
Target: p-STAT3 and oncogenic transcription factor inhibitorWP1122
Target: Glycolysis inhibitor (2-deoxy-D-glucose based)Recent News
No recent news updates available for this company.
Leadership Team
Walter V. Klemp
Chairman, President and Chief Executive Officer
Jonathan P. Foster
Executive Vice President and Chief Financial Officer
Dr. Donald H. Picker
Chief Scientific Officer
Dr. John Paul Waymack
Senior Chief Medical Officer
Dr. Waldemar Priebe
Co-Founder, Founding Scientist and Chairman of Scientific Advisory Board